Lates News

And Baroo Pharmaceuticals has entered into a collaboration with the clinical-stage biotechnology company Solstice Oncology. Baroo Pharmaceuticals will grant Solstice Oncology exclusive rights to develop and commercialize its clinical-stage combination asset HBM4003 outside of Greater China.